Date | Price Target | Rating | Analyst |
---|
4 - Denali Capital Acquisition Corp. (0001913577) (Issuer)
4 - Denali Capital Acquisition Corp. (0001913577) (Issuer)
NEW YORK, NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $15,063.74 to fund the one-month extension from September 11, 2024, to October 11, 2024. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closin
Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))) announce the signing of an agreement and plan of merger for a proposed business combination (the "Business Combination Agreement"), which provides for a pre-transaction equity value of Semnur of $2.5 billion. The Board of Scilex, Semnur, and Denali Capital Acquisition Corp. have approved the proposed transaction.The proposed business combination would create a publicly traded biopharma company and further provide investment into Semnur for the development of a non-opioid product, SP-102 (10 mg injectable dexam
Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))) announce the signing of an agreement and plan of merger for a proposed business combination (the "Business Combination Agreement"), which provides for a pre-transaction equity value of Semnur of $2.5 billion. The Board of Scilex, Semnur, and Denali Capital Acquisition Corp. have approved the proposed transaction. The proposed business combination would create a publicly traded biopharma company and further provide investment into Semnur for the development of a non-opioid product, SP-102 (10 mg injectable dex
NEW YORK, NEW YORK, , Aug. 09, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $15,063.74 to fund the one-month extension from August 11, 2024, to September 11, 2024. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing
NEW YORK, NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that the Company's shareholders voted in favor of approving amendments to the Company's amended and restated memorandum and articles of association (the "Articles") to extend the date by which the Company must consummate an initial business combination from July 11, 2024 to April 11, 2025 by electing to extend the date to consummate an initial business combination on a monthly basis for up to nine times by an additional one month each time (the "Extension"). The Company also announced today that it has deposited into the Company's trust account (
Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), and Denali Capital Acquisition Corp. (NASDAQ:DECA) ("SPAC") announce signing of a letter of intent for a proposed business combination, which provides for a pre-transaction equity value of Semnur of up to $2.0 billion, subject to adjustment based on third-party fairness opinion, with expected cash on hand at closing of up to $40 million depending on the number of SPAC shares that are redeemed prior to the completion of the business combination.The proposed business combination would create a publicly traded biopharma company and further provide investment into Semnur for th
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) ("Denali" or the "Company") announced today that Denali and Longevity Biomedical, Inc. have mutually agreed to terminate their previously announced business combination agreement (the "Business Combination Agreement"). The Company and its sponsor intend to seek alternative ways to consummate an initial business combination. About Denali Capital Acquisition Corp. Denali Capital Acquisition Corp. is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business comb
NEW YORK, NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that an aggregate of $50,000 has been deposited into the Company's trust account to further extend the period of time the Company has to consummate its business combination by an additional month from June 11, 2024 to July 11, 2024 in accordance with the amended terms of the Company's amended and restated memorandum and articles of association. About the Company Denali Capital Acquisition Corp. is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase,
NEW YORK, NEW YORK, May 10, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that an aggregate of $50,000 has been deposited into the Company's trust account to further extend the period of time the Company has to consummate its business combination by an additional month from May 11, 2024 to June 11, 2024 in accordance with the amended terms of the Company's amended and restated memorandum and articles of association. About the Company Denali Capital Acquisition Corp. is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, re
NEW YORK, NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that an aggregate of $50,000 has been deposited into the Company's trust account to further extend the period of time the Company has to consummate its business combination by an additional month from April 11, 2024 to May 11, 2024 in accordance with the amended terms of the Company's amended and restated memorandum and articles of association. About the Company Denali Capital Acquisition Corp. is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase,
Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))) announce the signing of an agreement and plan of merger for a proposed business combination (the "Business Combination Agreement"), which provides for a pre-transaction equity value of Semnur of $2.5 billion. The Board of Scilex, Semnur, and Denali Capital Acquisition Corp. have approved the proposed transaction.The proposed business combination would create a publicly traded biopharma company and further provide investment into Semnur for the development of a non-opioid product, SP-102 (10 mg injectable dexam
Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))) announce the signing of an agreement and plan of merger for a proposed business combination (the "Business Combination Agreement"), which provides for a pre-transaction equity value of Semnur of $2.5 billion. The Board of Scilex, Semnur, and Denali Capital Acquisition Corp. have approved the proposed transaction. The proposed business combination would create a publicly traded biopharma company and further provide investment into Semnur for the development of a non-opioid product, SP-102 (10 mg injectable dex
Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), and Denali Capital Acquisition Corp. (NASDAQ:DECA) ("SPAC") announce signing of a letter of intent for a proposed business combination, which provides for a pre-transaction equity value of Semnur of up to $2.0 billion, subject to adjustment based on third-party fairness opinion, with expected cash on hand at closing of up to $40 million depending on the number of SPAC shares that are redeemed prior to the completion of the business combination.The proposed business combination would create a publicly traded biopharma company and further provide investment into Semnur for th
Semnur Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company (NASDAQ:SCLX), and Denali Capital Acquisition Corp. (NASDAQ:DECA), a special purpose acquisition company, signed a letter of intent for a proposed business combination. The deal provides for a pre-transaction equity value of Semnur up to $2 billion, with expected gross proceeds of up to $40 million depending on the number of SPAC shares redeemed before the business combination is completed. Semnur is a clinical late-stage specialty pharmaceutical company focused on developing and commercializing novel non-opioid pain therapies. Semnur’s lead program, SP-102 (SEMDEXA), is the first non-opioid novel injectab
Scilex is expected to be the majority holder of the combined company following completion of the proposed business combination.
Denali Capital Acquisition Corp. (NASDAQ:DECA) ("Denali" or the "Company") announced today that Denali and Longevity Biomedical, Inc. have mutually agreed to terminate their previously announced business combination agreement (the "Business Combination Agreement"). The Company and its sponsor intend to seek alternative ways to consummate an initial business combination.
425 - Denali Capital Acquisition Corp. (0001913577) (Subject)
8-K - Denali Capital Acquisition Corp. (0001913577) (Filer)
10-Q - Denali Capital Acquisition Corp. (0001913577) (Filer)
NT 10-Q - Denali Capital Acquisition Corp. (0001913577) (Filer)
425 - Denali Capital Acquisition Corp. (0001913577) (Subject)
8-K - Denali Capital Acquisition Corp. (0001913577) (Filer)
8-K - Denali Capital Acquisition Corp. (0001913577) (Filer)
425 - Denali Capital Acquisition Corp. (0001913577) (Subject)
8-K - Denali Capital Acquisition Corp. (0001913577) (Filer)
8-K - Denali Capital Acquisition Corp. (0001913577) (Filer)
SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)
SC 13D - Denali Capital Acquisition Corp. (0001913577) (Subject)
SC 13G - Denali Capital Acquisition Corp. (0001913577) (Subject)
SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)
SC 13G - Denali Capital Acquisition Corp. (0001913577) (Subject)
SC 13G - Denali Capital Acquisition Corp. (0001913577) (Subject)
SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)
SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)
SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)
SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)